All In Biotech

Drug Trial Radar · NCT01901432

A Two-part Study to Assess the Safety and Preliminary Efficacy of Givinostat in Patients With Polycythemia Vera

A Two-part Study Top Assess the Safety and Preliminary Efficacy of Givinostat in Patients With JAK2V617F Positive Polycythemia Vera

Last checked: Nov 19, 2026Latest source record: Jul 30, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

48

Actual

Start

Oct 2013

Primary completion

Jun 26, 2017

Study completion Sep 25, 2017

Sponsor

Lead sponsor
ItalfarmacoIndustry
Sponsor type
Industry
First posted
Jul 17, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a two-part, multicenter, open label, non-randomized, phase Ib/II study to assess the safety and tolerability, Maximum Tolerated Dose and preliminary efficacy of Givinostat in patients with JAK2V617F positive Polycythemia Vera. Part A is the dose finding part while Part B is assessing the preliminary efficacy. Patients will be enrolled either in Part A or Part B and transition from one part to the other is not allowed. Eligible patients for this study will have a confirmed diagnosis of Polycythemia Vera according to the revised World Health Organization criteria. Only if the enrolment in Part A is slow (i.e. \< 5 patients enrolled in 3 months), eligibility for this part of the study may be expanded to all patients with chronic myeloproliferative neoplasms. Study therapy will be administered in 28 day cycles (4 weeks of treatment). Disease response will be evaluated according to the European LeukemiaNet criteria after 3 and 6 cycles (i.e. at weeks 12 and 24, respectively) of treatment with Givinostat for both parts of the study. All phlebotomies performed in the first 3 weeks of treatment will not be counted to assess the clinico-haematological response. The study will last up to a maximum of 24 weeks of treatment. However, after completion of the trial, all patients achieving clinical benefit will be allowed to continue treatment with Givinostat (at the same dose and schedule) in a long-term study. Safety will be monitored at each visit throughout the entire duration of the study. Treatment will be administered on an outpatient basis and patients will be followed regularly with physical and laboratory tests, as specified in the protocol; in case of hospitalization, the treatment will be continued or interrupted according to the Investigators' decision.

Conditions

  • Polycythemia Vera

Interventions

  • GivinostatDrug

    In Part A patients will treated in dose levels at the following daily doses of Givinostat: * 50 mg b.i.d., * 100 mg b.i.d.; * 150 mg b.i.d., * 200 mg b.i.d.; * 150 mg t.i.d.; * 200 mg t.i.d.. Intermediate dose levels and, consequently, additionally dose levels may be used to establish the Maximum Tolerated Dose. In Part B patients will be treated at the Maximum Tolerated Dose established in Part A. The product will be supplied as hard gelatine capsules for oral administration at the strength of 50 mg, 75 mg and/or 100 mg each.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Patients Experiencing Treatment-emergent Adverse Events (TEAEs) in Part A of the StudyTime frame: 168 days (up to Cycle 6 Day 28 in Part A).
  2. Number of Dose Limiting Toxicities (DLTs) After 1 Cycle in Part A of the StudyTime frame: 28 days (up to Cycle 1 Day 28 in Part A).
  3. Number of Patients Experiencing TEAEs After 3 Cycles in Part B of the StudyTime frame: 84 days (up to Cycle 3 Day 28 in Part B).
  4. Overall Response Rate (ORR) (i.e. Complete Response [CR] and Partial Response [PR]) After 3 Cycles in Part B of the StudyTime frame: 84 days (up to cycle 3 Day 28 in Part B).

Locations

25 sites in 5 countries. Site status is shown where the registry gives one.

  • CHU Amiens - Hôpital Sud

    Amiens, France

  • Hôpital Morvan - CHRU de Brest

    Brest, France

  • Hopital Saint Vincent de Paul - GHICL Lille

    Lille, France

  • Hôpital Saint-Louis (AP-HP), Centre Investigations Cliniques

    Paris, France

  • Charite Research Organisation GmbH

    Berlin, Germany

  • Universitaetsklinikum Koeln

    Cologne, Germany

  • Universitaetsklinikum Carl Gustav Carus TU Dresden

    Dresden, Germany

  • Universitaetsklinikum Freiburg

    Freiburg im Breisgau, Germany

  • Istituto Tumori Giovanni Paolo II - IRCCS Ospedale Oncologico di Bari

    Bari, Italy

  • Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico

    Milan, Italy

  • Università degli Studi di Napoli Federico II, Facoltà di Medicina e Chirurgia

    Naples, Italy

  • Ospedale Civile dello Spirito Santo

    Pescara, Italy

  • Azienda Ospedaliero Universitaria Pisana

    Pisa, Italy

  • Azienda Ospedaliera "Bianchi-Melacrino-Morelli"

    Reggio Calabria, Italy

  • Università Campus Bio-Medico di Roma

    Rome, Italy

  • Ospedale San Bortolo di Vicenza

    Vicenza, Italy

  • Azienda ospedaliero universitaria Consorziale Policlinico di Bari

    Bari, BA, Italy

  • Azienda Ospedaliera Papa Giovanni XXIII

    Bergamo, BG, Italy

  • Azienda Ospedaliero-Universitaria Careggi, Florence

    Florence, FI, Italy

  • Fondazione IRCCS Policlinico San Matteo

    Pavia, PV, Italy

  • SP ZOZ Zespol Szpitali Miejskich w Chorzowie

    Chorzów, Poland

  • Uniwersyteckie Centrum Kliniczne

    Gdansk, Poland

  • Belfast City Hospital

    Belfast, United Kingdom

  • Royal London Hospital

    London, United Kingdom

  • Royal Cornwall Hospital

    Truro, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.